NEW YORK – Poseida Therapeutics on Monday announced that the US Food and Drug Administration has allowed the firm to resume a Phase I clinical trial evaluating its CAR T-cell therapy, P-PSMA-101, in metastatic castration-resistant prostate cancer patients.